Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
about
Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin eraNew drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
P2860
Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Salvage treatment for relapsed ...... imab vedotin and newer agents.
@en
type
label
Salvage treatment for relapsed ...... imab vedotin and newer agents.
@en
prefLabel
Salvage treatment for relapsed ...... imab vedotin and newer agents.
@en
P2093
P2860
P1476
Salvage treatment for relapsed ...... ximab vedotin and newer agents
@en
P2093
Benedetto Bruno
Giuseppe Console
Michele Cimminiello
Moreno Festuccia
Paolo Gavarotti
Roberta Fedele
P2860
P304
P356
10.1517/14712598.2015.1130821
P407
P577
2016-02-06T00:00:00Z